BIOCORP and Merck KGaA, Darmstadt, Germany, Sign a New Partnership for Smart Drug Delivery
10 October 2022 - 04:30PM
Business Wire
- BIOCORP and Merck KGaA, Darmstadt, Germany, will collaborate on
the development and global distribution of a specific version of
Mallya for drug delivery devices
- BIOCORP and Merck KGaA, Darmstadt, Germany, are extending their
collaboration after an already ongoing program
- BIOCORP will receive payments for the development and
additional revenues from sales after launch following the
completion of certain milestones.
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR),
a French company specialized in the design, development, and
manufacturing of innovative medical devices, and Merck KGaA,
Darmstadt, Germany, a leading science, and technology company, have
entered into an agreement for the development and supply of a
specific version of Mallya device as an accessory for one of Merck
KGaA, Darmstadt, Germany's drug delivery devices.
Manufactured in Clermont-Ferrand (France), Mallya is a Bluetooth
enabled clip-on device for pen injectors that collects dose and
time of each injection and transfers information in real time to a
companion software. Mallya is the first in its category to receive
the CE-mark (medical device) and commercial versions for insulin
pen injectors are already available and distributed in Europe and
other geographies. Major agreements have already been signed by
BIOCORP with Sanofi, Novo Nordisk and Merck KGaA, Darmstadt,
Germany, to develop specific versions of the technology in the
field of Insulin and Human Growth Hormone (HGH).
Healthcare companies BIOCORP and Merck KGaA, Darmstadt, Germany,
will develop a new version of Mallya to help patients monitor their
injection during their treatment. The device will automatically
keep track of doses injected with timestamp and indicate that the
product is administered properly, aiming to support patients with
self-injections and to provide reassurance to patients.
Financial details of the partnership include payments from Merck
KGaA, Darmstadt, Germany, up to 5 million € for the development of
the product within the first three years of the collaboration.
Additional revenues are estimated to reach up to 8 million € during
the first 5 years after launch depending on commercial milestones
and adoption of Mallya devices by Merck KGaA, Darmstadt, Germany
patients with further upside potential in the subsequent years.
"We are delighted with this new partnership with Merck KGaA,
Darmstadt, Germany, extending our collaboration to additional
therapeutic areas. We had already announced that there is a great
opportunity for our connected device Mallya in various therapeutic
areas. As in diabetes, Mallya aims to reduce patients' stress and
improve compliance with their treatments to optimize and secure the
results “, said Éric Dessertenne, CEO of BIOCORP.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This smart sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of patients with diabetes. Available
for sale from 2020, Mallya spearheads BIOCORP's product portfolio
of innovative connected solutions. The company has 74 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 –
ALCOR).
For more information, please visit www.biocorpsys.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221009005016/en/
CONTACTS BIOCORP Jacques Gardette Chairman of the Board
investisseurs@biocorp.fr
Éric Dessertenne Chief Executive Officer
Sylvaine Dessard Marketing & Communication Director
rp@biocorp.fr + 33 (0)6 88 69 72 85
CONTACTS ULYSSE COMMUNICATION Bruno ARABIAN
barabian@ulysse-communication.com +33 (0)6 87 88 47 26
Biocorp (EU:ALCOR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Biocorp (EU:ALCOR)
Historical Stock Chart
From Mar 2023 to Mar 2024